NCT05472272 is a NA clinical trial of Formula diet in Type 2 Diabetes Mellitus, sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine.

Who is sponsoring NCT05472272?

NCT05472272 is sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine.

What drugs are being tested in NCT05472272?

Interventions in NCT05472272: Formula diet, Food-based diet.

What condition does NCT05472272 study?

NCT05472272 studies Type 2 Diabetes Mellitus, Obesity, Overweight.

Is NCT05472272 still recruiting?

NCT05472272 is currently completed. Last updated 16 May 2024.

Last reviewed 2024-05-16 · How we verify

NCT05472272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-Calorie Diets on Type 2 Diabetes Remission

Completed NA Last updated 16 May 2024

What this trial tests

NA trial testing Formula diet in Type 2 Diabetes Mellitus in 42 participants. Completed in 18 February 2024.

Timeline

3 August 2022

Primary endpoint
18 February 2024

18 February 2024

Quick facts

Lead sponsor	Shanghai Municipal Hospital of Traditional Chinese Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	3 August 2022
Primary completion	18 February 2024
Estimated completion	18 February 2024
Sites	1 location across China

Drugs / interventions tested

Formula diet
Food-based diet

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Obesity — all drugs for Obesity →
Overweight — all drugs for Overweight →

Sponsor

Shanghai Municipal Hospital of Traditional Chinese Medicine

Who can join

Adults 18 to 60, any sex, with Type 2 Diabetes Mellitus or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of type 2 diabetes mellitus (T2DM) has been increasing rapidly in China. China currently has \~130 million diabetes cases, and over 90% are T2DM. T2DM is a leading cause of morbidity and mortality, posing substantial clinical and public health challenges. Reversing T2DM with a significant amount of weight loss via consuming a low-calorie diet is possible, but no studies have been conducted to determine whether low-calorie diets will help achieve significant weight loss and diabetes remission among Chinese patients with T2DM. The investigators design a pilot study to assess the feasibility of a low-calorie diet intervention program on weight loss and diabetes remission in a Chinese population with T2DM.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Low-calorie diets and remission of type 2 diabetes in Chinese: phenotypic changes and individual variability.
Liu Z, Feng N, Wang S, Liu Y, et al · · 2025 · cited 2× · PMID 40087696 · DOI 10.1186/s12937-025-01101-z
Role of Plasma-Derived Exosomal MicroRNAs in Mediating Type 2 Diabetes Remission.
Wang S, Shi S, Jiang X, Yang G, et al · · 2025 · PMID 40806035 · DOI 10.3390/nu17152450
Epigenetic Signatures of Type 2 Diabetes Remission and Substantial Weight Loss: The Role of DNA Methylation in Response to Low-Calorie Diet Intervention.
Shi S, Wang S, Wu D, Li K, et al · · 2025 · PMID 40471649 · DOI 10.1080/27697061.2025.2513378

Verify or expand the search:

Other trials of Formula diet

Trials testing the same drug.

NCT04707651 — Formula Diet Treatment for NASH Patients. · NA · active not recruiting

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Shanghai Municipal Hospital of Traditional Chinese Medicine trials

Trials by the same sponsor.

NCT07320456 — A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease · Phase 2 · not yet recruiting
NCT07050563 — Clinical Evaluation of the Tiaoshen Anti-Cancer Regimen in Treating Psycho-Neurological Symptom Cluster in Ovarian Cance · NA · not yet recruiting
NCT07050121 — A Prospective Multi-Center Real-World Study of Ciwujia Capsules in the Treatment of Cancer-Related Insomnia · not yet recruiting
NCT07003763 — Electroacupuncture on Treating Cancer-related Depression · NA · recruiting
NCT06442137 — A Clinical Trial of Chazhu Xiaozhi Decoction Against Non-alcoholic Fatty Liver Disease · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05472272 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Municipal Hospital of Traditional Chinese Medicine
Last refreshed: 16 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05472272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing